(Total Views: 325)
Posted On: 10/16/2020 6:41:21 AM
Post# of 36568
Amazing GILD was able to get EUA based on the limited success they had previously.
Looks like CYDY will have to continue leronlimab's trial based on the PR last night so no immediate EUA help there for Covid. CC was set for Tuesday to discuss. Stock price going to reflect not getting emergency approval. Data must be at least good or they would have stopped study completely. Having to wait a 2-3 more months for a therapy sucks. They really slowed down enrolling new trial participants which was a mistake. Possible they may change the primary endpoint since fewer patients are dying now thanks to better standard of care in the ICU vs back when the trial was designed.
Looks like CYDY will have to continue leronlimab's trial based on the PR last night so no immediate EUA help there for Covid. CC was set for Tuesday to discuss. Stock price going to reflect not getting emergency approval. Data must be at least good or they would have stopped study completely. Having to wait a 2-3 more months for a therapy sucks. They really slowed down enrolling new trial participants which was a mistake. Possible they may change the primary endpoint since fewer patients are dying now thanks to better standard of care in the ICU vs back when the trial was designed.
(0)
(0)
